Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 11:35:25 2024-04-18 am EDT 5-day change 1st Jan Change
321.2 GBX +0.41% Intraday chart for Haleon plc -0.62% -0.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HSBC Starts Haleon Coverage with Buy Rating MT
HSBC likes Haleon, cuts Flutter to 'hold' AN
Embattled Hipgnosis Songs Fund agrees takeover AN
HALEON : Haleon on-track to deliver healthy and steady shareholder returns Alphavalue
Deutsche Bank Trims Haleon PT, Keeps Hold Rating MT
Futura Medical hails results as erectile dysfunction drug drives sales AN
Exane BNP raises Shell to 'outperform' AN
Barclays Trims Haleon PT, Keeps Overweight Rating MT
Barclays raises Halma to 'overweight' AN
Kepler Cheuvreux Lifts Haleon PT, Keeps Hold Rating MT
Bernstein starts AstraZeneca at 'outperform' AN
Global IPO revival lags first quarter share sales as markets rally RE
Haleon buys back shares worth GBP315 million from Pfizer AN
Repeat & Correct : Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale -- Update DJ
Haleon Says Pfizer to Cut Stake to 23% After Pricing Upsized Secondary Offering of Haleon Shares MT
Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale -- Update DJ
Haleon to buy back shares from Pfizer for GBP315 million AN
Repeat & Correct : Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale DJ
Pfizer offloads $3.9 bln stake in Sensodyne-maker Haleon RE
Pfizer Upsizes, Prices Global Offering of Haleon Shares MT
Pfizer Made Around $3.5 Billion From Haleon Shares Sale DJ
Stocks downbeat before central bank rate storm AN
UK's FTSE 100 Index Closes Flat Ahead of BoE's Monetary Policy Decision MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
Pfizer to Sell About 630 Million of Haleon Shares Via Secondary Offering MT
Chart Haleon plc
More charts
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.212 GBP
Average target price
3.594 GBP
Spread / Average Target
+11.89%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. News Haleon plc
  5. Haleon Reiterates Non-involvement in Zantac Claims, Rejects Indemnification Requests